TY - JOUR T1 - Risk of severe liver injury with ▼ daclizumab (Zinbryta) JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 110 LP - 110 DO - 10.1136/dtb.2017.10.0531 VL - 55 IS - 10 A2 - , Y1 - 2017/10/01 UR - http://dtb.bmj.com/content/55/10/110.1.abstract N2 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning on the risk of severe liver injury with daclizumab.1 The MHRA has advised that, while an urgent EU-wide review of new information on liver safety is under way, initiation of daclizumab in multiple sclerosis (MS) should be restricted to patients with limited treatment options. Prescribers should promptly review patients already on treatment to assess whether it continues to be appropriate for them. The review should include a discussion with … ER -